The passive immunization of patients with SARS-CoV-2 CP is theoretically beneficial in patients with end stage renal disease who are immunosuppressed and unable to mount an adequate immune response; however, according to preliminary results, CP does not appear to confer any clinical benefit in moderate-to-severe SARS-CoV-2 infected patients with chronic kidney disease on hemodialysis [53]. The gene discussed is CP; the disease is stage 5 chronic kidney disease.